Medical/Pharmaceuticals
Suvoda Announces 30% Growth in 2023 Driven by Strong Customer Adoption of New Suvoda Platform and Products
Company maintained industry-leading quality metrics throughout growth surge. PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, su...
2024-01-08 08:00
1595
Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis
- Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. - Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worl...
2024-01-08 07:00
1478
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
HONG KONG, Jan. 5, 2024 /PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab(开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XEL...
2024-01-05 21:00
5766
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement onEribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countr...
2024-01-05 19:44
3095
Grant of Restricted Share Units to Mr. Xing Jin
BEIJING, Jan. 5, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that the Compensation Committe...
2024-01-05 19:00
6161
SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease
* Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights forGreater China and Singapore * Transaction reflects the Novartis commitment to the Chinese market and complements existing pipeline in renal diseases. SHANGHAI, Jan. 5, 2024 /PRNewswire/ -- San...
2024-01-05 16:00
2568
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorpho...
2024-01-05 14:35
1822
Therabody, the Global Leader In Wellness Technology, Defends Against Recent Patent Infringement Lawsuit Filed by Hyperice
As the leading percussive patent owner and the driving force behind many of today's wellness innovations, Therabody will vigorously defend itself against the recent patent infringement lawsuit filed by Hyperice. LOS ANGELES, Jan. 5, 2024 /PRNewswire/ -- Therabody, the leader in tech wellness and...
2024-01-05 06:33
2570
Greenway Health Earns Frost & Sullivan's 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Products and Services that Enhance Health Providers and Patients Experiences
Greenway Health™ (Greenway®) offers groundbreaking client-centric electronic health record (EHR) and practice management software that streamline workflows and improve patient outcomes through a unique blend of in-depth insights and cutting-edge technology. SAN ANTONIO, Jan. 5, 2024 /PRNewswire/...
2024-01-05 04:30
2808
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...
2024-01-05 00:19
2579
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the ...
2024-01-04 21:40
2674
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
* Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors * Proceeds to advance CUSP06, the company's antibody drug conjugate (ADC) targetingCDH6, to clinical proof-of-concept NEW YORK, Jan. 4, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc...
2024-01-04 21:11
1695
Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On December 28, 2023, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Vicagrel capsule, which is indicated to treat a range of thrombotic cardiova...
2024-01-04 21:05
1785
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
- AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase 1 clinical study in advanced solid tumors - Avenzo also obtains an exclusive option to an additional preclinical program planned ...
2024-01-04 21:02
1789
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held inSan Francisco, California, USA, from Ja...
2024-01-04 17:37
4626
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference inSan Francisco, USA. The forum, themed " Innovations and Breakthroughs Shaping Tomorrow's Cell and Gene Therapi...
2024-01-04 16:55
1753
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis. * Derived from the platform, LAE105 is a potentially first-in-class drug candidate that depletes aHSC in the fibrotic liver by harnessing innate ...
2024-01-04 12:40
1676
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MELBOURNE, Australia, Jan. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference inSan Francisco, CA (US). The pre...
2024-01-04 06:20
1970
IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies
SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 3, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products,today announced a new set of collaborations wi...
2024-01-04 05:30
2340
GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN
ADELAIDE, Australia, Jan. 3, 2024 /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase...
2024-01-04 04:30
1938
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 298 media titles]
2025-01-23 09:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 291 media titles]
2025-01-20 21:09
Most Read
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
2025-01-18 03:30
12436
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
2025-01-18 17:00
11637
EZGO ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2024
2025-01-18 06:45
8862
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
5535
MONTECH Debuts the Heritage: A New Era of Leather Craft & High-End PC
2025-01-18 22:00
5505
